BCM
PTCT icon

Bridgeway Capital Management’s PTC Therapeutics PTCT Stock Holding History

Bridgeway Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Sell
22,000
-6,100
-22% -$432K 0.03% 608
2025
Q4 		$2.13M Sell
28,100
-13,700
-33% -$996K 0.04% 514
2025
Q3 		$2.57M Buy
+41,800
New +$2.18M 0.05% 471
2016
Q2 		– Sell
-85,800
Closed -$553K – 1471
2016
Q1 		$553K Buy
+85,800
New +$1.49M 0.01% 1000

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Bridgeway Capital Management's PTCT Position: Q1 2026 in Review

Bridgeway Capital Management reduced its PTC Therapeutics (PTCT) stake by 22% in Q1 2026, selling an estimated $432K and leaving 22,000 shares worth $1.5M. The position accounts for 0.03% of the portfolio, ranked #608.

Bridgeway Capital Management first reported a position in PTCT in Q1 2016 and has held it in 4 quarters since. The position peaked at $2.57M in Q3 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Bridgeway Capital Management held 22,000 shares of PTC Therapeutics worth $1.5M as of Q1 2026.
  • Bridgeway Capital Management sold 6,100 PTC Therapeutics shares in Q1 2026, an estimated $432K.
  • PTC Therapeutics made up 0.03% of Bridgeway Capital Management's portfolio in Q1 2026, its #608 holding.
  • Bridgeway Capital Management first reported a position in PTC Therapeutics in Q1 2016 and has held it in 4 quarters since.
  • Bridgeway Capital Management's PTC Therapeutics position peaked at $2.57M in Q3 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.